Free Trial Information
BioCentury | Dec 28, 2020
Deals

Myovant’s deal with Pfizer for $650M up front is the latest sign women’s health is back

...tablet includes 40 mg relugolix, 1.0 mg estradiol...
Read More
BioCentury | Aug 18, 2020
Product Development

Gilead, Tango expand cancer partnership; plus Roche approval, Novavax COVID-19 efficacy study and G1, Myovant and PTC applications under review

...heavy menstrual bleeding associated with uterine fibroids. The PDUFA date for the combination of the GNRHR antagonist plus estradiol...
Read More
BioCentury | Jun 24, 2020
Regulation

Myovant eyes third NDA for relugolix after endometriosis readout

...III trial for the disease. In the SPIRIT 1 study, a combination of relugolix plus estradiol...
Read More
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

...menstruation therapy AbbVie Inc. (NYSE:ABBV) and Neurocrine Biosciences Inc. (NASDAQ:NBIX) said FDA approved Oriahnn elagolix, estradiol...
Read More
BioCentury | Apr 23, 2020
Product Development

April 22 Quick Takes: Accelerated approval for Immunomedics’ Trodelvy; plus BioNTech-Pfizer, AskBio, Astellas, Merck KGaA, oNKo-Gilead, Myovant, Afyx and Sangam

...therapy programs. Myovant planning relugolix NDA for endometriosis Myovant Sciences Ltd. (NYSE:MYOV) said relugolix plus estradiol...
Read More
BioCentury | Jul 23, 2019
Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

...Phase III for uterine fibroids Myovant Sciences Ltd. (NYSE:MYOV) said relugolix (TAK-385) in combination with estradiol/norethindrone...
Read More
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...lambrolizumab) lebrikizumab (MILR1444A, RG3637, tnx-650, anti-IL13) Ryaltris, mometasone/olopatadine (gsp 301) Seven-day contraceptive patch, Twirla (AG200-15, ag-200-15, Agile Patch, estradiol/levonorgestrel) Agile...
Read More
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
Read More
BioCentury | Oct 9, 2018
Politics & Policy

FDA pushes generic competition for transdermal complex drugs

...irritation and sensitization potential; and 25 product-specific guidances, including two new guidances for capsaicin and estradiol/norethindrone...
Read More
BioCentury | Oct 6, 2018
Finance

Seeking validation

...NASDAQ:SBPH) Inarigivir soproxil Chronic HBV Additional Ph II ACHIEVE data November TherapeuticsMD Inc. (NASDAQ:TXMD) TX-001HR estradiol/progesterone...
Read More
Items per page:
1 - 10 of 442